Fujian Haixi Pharma discloses RMB 577.22 million investments equal to 31.3% of 2025 total assets

• Fujian Haixi Pharmaceuticals issued a supplemental clarification to its 2025 annual report, detailing financial instrument investments equal to 31.3% of total assets.
• Disclosed fair values at Dec. 31: money market funds RMB 352.37 million, structured financial product RMB 181.19 million, equity instrument RMB 20.28 million.
• Also reported a non-current convertible note at RMB 23.38 million, with a RMB 3.38 million fair value gain in 2025.
• Stated IPO proceeds were not used for these investments; funding came from internal working capital or idle funds.
• Added property valuation disclosure: IPO-era valuation RMB 198.11 million; no revaluation needed, depreciation on capitalized buildings about RMB 1.45 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12267040), on August 03, 2026, and is solely responsible for the information contained therein.